Selected research
Industry Growth & Trends
Global Tachykinin Receptor 1 Antibody Industry Growth and Trends Forecast to 2032
Market perspective
According to APO Research, the global Tachykinin Receptor 1 Antibody market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.
The North America market for Tachykinin Receptor 1 Antibody is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026-2032.
The Europe market for Tachykinin Receptor 1 Antibody is projected to increase from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026-2032.
Read the full market overview
The Asia Pacific market for Tachykinin Receptor 1 Antibody is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Leading global companies in the Tachykinin Receptor 1 Antibody market include Merck, Boster Biological Technology, United States Biological, Santa Cruz Biotechnology, Proteintech, ProSci, NSJ Bioreagents, LSBio and GeneTex, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report provides a structured, data-driven view of the global Tachykinin Receptor 1 Antibody market, combining harmonized quantitative metrics with targeted qualitative insight to support business and growth strategy, market positioning, and capital allocation.
The Tachykinin Receptor 1 Antibody market size, estimates, and forecasts are presented in terms of revenue (US$ million), with 2025 as the base year and historical and forecast data for 2021-2032. The report segments the global Tachykinin Receptor 1 Antibody market by Type, Application, region/country, and company, provides regional market sizes at the segment level, profiles the competitive landscape and key players and their market ranks, and reviews technology trends and new product developments relevant to Tachykinin Receptor 1 Antibody.
Key Companies & Market Share Insights
This section analyzes the strategies and performance of leading companies in the global Tachykinin Receptor 1 Antibody market, including portfolio focus, innovation and product development, mergers and acquisitions, collaborations, and geographic expansion used to sustain or enhance competitive positions. It also summarizes recent corporate developments and key financial indicators and provides global revenue and gross margin data by manufacturer for 2021-2026, enabling benchmarking of scale, profitability, and market share and supporting assessment of market concentration through indicators such as CR5 and CR10.
Tachykinin Receptor 1 Antibody Market by Company
Merck
Boster Biological Technology
United States Biological
Santa Cruz Biotechnology
Proteintech
ProSci
NSJ Bioreagents
LSBio
GeneTex
FineTest
Everest Biotech
Cusabio
Atlas Antibodies
Advanced Targeting Solutions
Tachykinin Receptor 1 Antibody Segment by Type
Polyclonal
Monoclonal
Tachykinin Receptor 1 Antibody Segment by Application
Western Blot
Flow Cytometry
Immunocytochemistry
Immunofluorescence
Others
Tachykinin Receptor 1 Antibody Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Tachykinin Receptor 1 Antibody market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Tachykinin Receptor 1 Antibody and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Tachykinin Receptor 1 Antibody.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2021-2025, 2026-2031). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 3: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 4: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 5: Detailed analysis of Tachykinin Receptor 1 Antibody companies' competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, South America, Middle East & Africa, revenue by country.
Chapter 12: Concluding Insights of the report
More report detail
Tables and figures
Scope & coverage.
Types
- Polyclonal
- Monoclonal
Applications
- Western Blot
- Flow Cytometry
- Immunocytochemistry
- Immunofluorescence
- Others
Companies covered
- Merck
- Boster Biological Technology
- United States Biological
- Santa Cruz Biotechnology
- Proteintech
- ProSci
- NSJ Bioreagents
- LSBio
- GeneTex
- FineTest
- Everest Biotech
- Cusabio
- Atlas Antibodies
- Advanced Targeting Solutions
Inside the report.
1 Market Overview
- 1.1 Product Definition
- 1.2 Global Market Growth Prospects
- 1.3 Global Tachykinin Receptor 1 Antibody Market Size Overview by Region 2021 VS 2025 VS 2032
- 1.4 Global Tachykinin Receptor 1 Antibody Market Size by Region (2021-2032)
- 1.4.1 Global Tachykinin Receptor 1 Antibody Market Size by Region (2021-2026)
- 1.4.2 Global Tachykinin Receptor 1 Antibody Market Size by Region (2027-2032)
- 1.5 Key Regions Tachykinin Receptor 1 Antibody Market Size (2021-2032)
- 1.5.1 North America Tachykinin Receptor 1 Antibody Market Size Growth Rate (2021-2032)
- 1.5.2 Europe Tachykinin Receptor 1 Antibody Market Size Growth Rate (2021-2032)
- 1.5.3 Asia-Pacific Tachykinin Receptor 1 Antibody Market Size Growth Rate (2021-2032)
- 1.5.4 South America Tachykinin Receptor 1 Antibody Market Size Growth Rate (2021-2032)
- 1.5.5 Middle East & Africa Tachykinin Receptor 1 Antibody Market Size Growth Rate (2021-2032)
2 Tachykinin Receptor 1 Antibody Market by Type
- 2.1 Type Introduction
- 2.1.1 Polyclonal
- 2.1.2 Monoclonal
- 2.2 Global Tachykinin Receptor 1 Antibody Market Size by Type
- 2.2.1 Global Tachykinin Receptor 1 Antibody Market Size Overview by Type (2021-2032)
- 2.2.2 Global Tachykinin Receptor 1 Antibody Historic Market Size Review by Type (2021-2026)
- 2.2.3 Global Tachykinin Receptor 1 Antibody Market Size Forecasted by Type (2027-2032)
- 2.3 Global Tachykinin Receptor 1 Antibody Market Size by Regions
- 2.3.1 North America Tachykinin Receptor 1 Antibody Market Size Breakdown by Type (2021-2026)
- 2.3.2 Europe Tachykinin Receptor 1 Antibody Market Size Breakdown by Type (2021-2026)
- 2.3.3 Asia-Pacific Tachykinin Receptor 1 Antibody Market Size Breakdown by Type (2021-2026)
- 2.3.4 South America Tachykinin Receptor 1 Antibody Market Size Breakdown by Type (2021-2026)
- 2.3.5 Middle East and Africa Tachykinin Receptor 1 Antibody Market Size Breakdown by Type (2021-2026)
3 Tachykinin Receptor 1 Antibody Market by Application
- 3.1 Type Introduction
- 3.1.1 Western Blot
- 3.1.2 Flow Cytometry
- 3.1.3 Immunocytochemistry
- 3.1.4 Immunofluorescence
- 3.1.5 Others
- 3.2 Global Tachykinin Receptor 1 Antibody Market Size by Application
- 3.2.1 Global Tachykinin Receptor 1 Antibody Market Size Overview by Application (2021-2032)
- 3.2.2 Global Tachykinin Receptor 1 Antibody Historic Market Size Review by Application (2021-2026)
- 3.2.3 Global Tachykinin Receptor 1 Antibody Market Size Forecasted by Application (2027-2032)
- 3.3 Global Tachykinin Receptor 1 Antibody Market Size by Regions
- 3.3.1 North America Tachykinin Receptor 1 Antibody Market Size Breakdown by Application (2021-2026)
- 3.3.2 Europe Tachykinin Receptor 1 Antibody Market Size Breakdown by Application (2021-2026)
- 3.3.3 Asia-Pacific Tachykinin Receptor 1 Antibody Market Size Breakdown by Application (2021-2026)
- 3.3.4 South America Tachykinin Receptor 1 Antibody Market Size Breakdown by Application (2021-2026)
- 3.3.5 Middle East and Africa Tachykinin Receptor 1 Antibody Market Size Breakdown by Application (2021-2026)
4 Global Market Dynamics
- 4.1 Tachykinin Receptor 1 Antibody Industry Trends
- 4.2 Tachykinin Receptor 1 Antibody Industry Drivers
- 4.3 Tachykinin Receptor 1 Antibody Industry Opportunities and Challenges
- 4.4 Tachykinin Receptor 1 Antibody Industry Restraints
5 Competitive Insights by Company
- 5.1 Global Top Players by Tachykinin Receptor 1 Antibody Revenue (2021-2026)
- 5.2 Global Tachykinin Receptor 1 Antibody Industry Company Ranking, 2024 VS 2025 VS 2026
- 5.3 Global Tachykinin Receptor 1 Antibody Key Company Headquarters & Area Served
- 5.4 Global Tachykinin Receptor 1 Antibody Company, Product Type & Application
- 5.5 Global Tachykinin Receptor 1 Antibody Company Commercialization Time
- 5.6 Market Competitive Analysis
- 5.6.1 Global Tachykinin Receptor 1 Antibody Market CR5 and HHI
- 5.6.2 Global Top 5 and 10 Tachykinin Receptor 1 Antibody Players Market Share by Revenue in 2025
- 5.6.3 2025 Tachykinin Receptor 1 Antibody Tier 1, Tier 2, and Tier 3
6 Company Profiles
- 6.1 Merck
- 6.1.1 Merck Company Information
- 6.1.2 Merck Business Overview
- 6.1.3 Merck Tachykinin Receptor 1 Antibody Revenue, Global Share and Gross Margin (2021-2026)
- 6.1.4 Merck Tachykinin Receptor 1 Antibody Product Portfolio
- 6.1.5 Merck Recent Developments
- 6.2 Boster Biological Technology
- 6.2.1 Boster Biological Technology Company Information
- 6.2.2 Boster Biological Technology Business Overview
- 6.2.3 Boster Biological Technology Tachykinin Receptor 1 Antibody Revenue, Global Share and Gross Margin (2021-2026)
- 6.2.4 Boster Biological Technology Tachykinin Receptor 1 Antibody Product Portfolio
- 6.2.5 Boster Biological Technology Recent Developments
- 6.3 United States Biological
- 6.3.1 United States Biological Company Information
- 6.3.2 United States Biological Business Overview
- 6.3.3 United States Biological Tachykinin Receptor 1 Antibody Revenue, Global Share and Gross Margin (2021-2026)
- 6.3.4 United States Biological Tachykinin Receptor 1 Antibody Product Portfolio
- 6.3.5 United States Biological Recent Developments
- 6.4 Santa Cruz Biotechnology
- 6.4.1 Santa Cruz Biotechnology Company Information
- 6.4.2 Santa Cruz Biotechnology Business Overview
- 6.4.3 Santa Cruz Biotechnology Tachykinin Receptor 1 Antibody Revenue, Global Share and Gross Margin (2021-2026)
- 6.4.4 Santa Cruz Biotechnology Tachykinin Receptor 1 Antibody Product Portfolio
- 6.4.5 Santa Cruz Biotechnology Recent Developments
- 6.5 Proteintech
- 6.5.1 Proteintech Company Information
- 6.5.2 Proteintech Business Overview
- 6.5.3 Proteintech Tachykinin Receptor 1 Antibody Revenue, Global Share and Gross Margin (2021-2026)
- 6.5.4 Proteintech Tachykinin Receptor 1 Antibody Product Portfolio
- 6.5.5 Proteintech Recent Developments
- 6.6 ProSci
- 6.6.1 ProSci Company Information
- 6.6.2 ProSci Business Overview
- 6.6.3 ProSci Tachykinin Receptor 1 Antibody Revenue, Global Share and Gross Margin (2021-2026)
- 6.6.4 ProSci Tachykinin Receptor 1 Antibody Product Portfolio
- 6.6.5 ProSci Recent Developments
- 6.7 NSJ Bioreagents
- 6.7.1 NSJ Bioreagents Company Information
- 6.7.2 NSJ Bioreagents Business Overview
- 6.7.3 NSJ Bioreagents Tachykinin Receptor 1 Antibody Revenue, Global Share and Gross Margin (2021-2026)
- 6.7.4 NSJ Bioreagents Tachykinin Receptor 1 Antibody Product Portfolio
- 6.7.5 NSJ Bioreagents Recent Developments
- 6.8 LSBio
- 6.8.1 LSBio Company Information
- 6.8.2 LSBio Business Overview
- 6.8.3 LSBio Tachykinin Receptor 1 Antibody Revenue, Global Share and Gross Margin (2021-2026)
- 6.8.4 LSBio Tachykinin Receptor 1 Antibody Product Portfolio
- 6.8.5 LSBio Recent Developments
- 6.9 GeneTex
- 6.9.1 GeneTex Company Information
- 6.9.2 GeneTex Business Overview
- 6.9.3 GeneTex Tachykinin Receptor 1 Antibody Revenue, Global Share and Gross Margin (2021-2026)
- 6.9.4 GeneTex Tachykinin Receptor 1 Antibody Product Portfolio
- 6.9.5 GeneTex Recent Developments
- 6.10 FineTest
- 6.10.1 FineTest Company Information
- 6.10.2 FineTest Business Overview
- 6.10.3 FineTest Tachykinin Receptor 1 Antibody Revenue, Global Share and Gross Margin (2021-2026)
- 6.10.4 FineTest Tachykinin Receptor 1 Antibody Product Portfolio
- 6.10.5 FineTest Recent Developments
- 6.11 Everest Biotech
- 6.11.1 Everest Biotech Company Information
- 6.11.2 Everest Biotech Business Overview
- 6.11.3 Everest Biotech Tachykinin Receptor 1 Antibody Revenue, Global Share and Gross Margin (2021-2026)
- 6.11.4 Everest Biotech Tachykinin Receptor 1 Antibody Product Portfolio
- 6.11.5 Everest Biotech Recent Developments
- 6.12 Cusabio
- 6.12.1 Cusabio Company Information
- 6.12.2 Cusabio Business Overview
- 6.12.3 Cusabio Tachykinin Receptor 1 Antibody Revenue, Global Share and Gross Margin (2021-2026)
- 6.12.4 Cusabio Tachykinin Receptor 1 Antibody Product Portfolio
- 6.12.5 Cusabio Recent Developments
- 6.13 Atlas Antibodies
- 6.13.1 Atlas Antibodies Company Information
- 6.13.2 Atlas Antibodies Business Overview
- 6.13.3 Atlas Antibodies Tachykinin Receptor 1 Antibody Revenue, Global Share and Gross Margin (2021-2026)
- 6.13.4 Atlas Antibodies Tachykinin Receptor 1 Antibody Product Portfolio
- 6.13.5 Atlas Antibodies Recent Developments
- 6.14 Advanced Targeting Solutions
- 6.14.1 Advanced Targeting Solutions Company Information
- 6.14.2 Advanced Targeting Solutions Business Overview
- 6.14.3 Advanced Targeting Solutions Tachykinin Receptor 1 Antibody Revenue, Global Share and Gross Margin (2021-2026)
- 6.14.4 Advanced Targeting Solutions Tachykinin Receptor 1 Antibody Product Portfolio
- 6.14.5 Advanced Targeting Solutions Recent Developments
7 North America
- 7.1 North America Tachykinin Receptor 1 Antibody Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 7.2 North America Tachykinin Receptor 1 Antibody Market Size by Country (2021-2026)
- 7.3 North America Tachykinin Receptor 1 Antibody Market Size Forecast by Country (2027-2032)
8 Europe
- 8.1 Europe Tachykinin Receptor 1 Antibody Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 8.2 Europe Tachykinin Receptor 1 Antibody Market Size by Country (2021-2026)
- 8.3 Europe Tachykinin Receptor 1 Antibody Market Size Forecast by Country (2027-2032)
9 Asia-Pacific
- 9.1 Asia-Pacific Tachykinin Receptor 1 Antibody Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 9.2 Asia-Pacific Tachykinin Receptor 1 Antibody Market Size by Country (2021-2026)
- 9.3 Asia-Pacific Tachykinin Receptor 1 Antibody Market Size Forecast by Country (2027-2032)
10 South America
- 10.1 South America Tachykinin Receptor 1 Antibody Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 10.2 South America Tachykinin Receptor 1 Antibody Market Size by Country (2021-2026)
- 10.3 South America Tachykinin Receptor 1 Antibody Market Size Forecast by Country (2027-2032)
11 Middle East & Africa
- 11.1 Middle East & Africa Tachykinin Receptor 1 Antibody Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 11.2 Middle East & Africa Tachykinin Receptor 1 Antibody Market Size by Country (2021-2026)
- 11.3 Middle East & Africa Tachykinin Receptor 1 Antibody Market Size Forecast by Country (2027-2032)
12 Concluding Insights
13 Appendix
- 13.1 Reasons for Doing This Study
- 13.2 Research Methodology
- 13.3 Research Process
- 13.4 Authors List of This Report
- 13.5 Data Source
- 13.5.1 Secondary Sources
- 13.5.2 Primary Sources
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst